Circulation:诊室血压<130/80 mm Hg患者的隐匿性高血压发病率

2018-05-13 国际循环编辑部 国际循环

最新指南提出,将高血压定义为诊室血压测量收缩压≥130 mm Hg或舒张压≥80 mm Hg新值,以及药物治疗目标值<130/80 mm Hg。24 h动态血压监测(ABPM)和家庭血压自测通常用于检测“白大衣”高血压。相反,隐匿性高血压(MH)是指正常诊室血压和家中自测或24 h ABPM正常的血压。近日,Circulation杂志发表的一项基于24 h ABPM诊室血压<130 / <80 m

最新指南提出,将高血压定义为诊室血压测量收缩压≥130 mm Hg或舒张压≥80 mm Hg新值,以及药物治疗目标值<130/80 mm Hg。24 h动态血压监测(ABPM)和家庭血压自测通常用于检测“白大衣”高血压。相反,隐匿性高血压(MH)是指正常诊室血压和家中自测或24 h ABPM正常的血压。近日,Circulation杂志发表的一项基于24 h ABPM诊室血压<130 / <80 mm Hg患者(指南建议),对西班牙ABPM登记处的MH和隐匿不可控制性高血压(MUCH)的发病情况进行了探讨。

研究纳入115 708例患者,其中90%来自初级保健中心,10%来自高血压或心血管病诊所。对应于诊室血压界值130/80 mm Hg,提出24 h、日间和夜间血压值分别为125/75 mm Hg、130/80 mm Hg和110/65 mm Hg。MH和MUCH的诊断根据美国心脏病学学会(ACC)/美国心脏协会(AHA)高血压指南,平均24 h ABPM≥125 mm Hg或≥75 mm Hg,平均日间血压≥130 mm Hg或≥80 mm Hg,平均夜间血压≥110 mm Hg或≥65 mm Hg,或上述任何一项进行。欧洲高血压学会(ESH)的推荐是,平均日间ABPM升高5 mm Hg,夜间ABPM升高10 mm Hg。

结果,受试者平均年龄为59(14)岁,女性占47%。诊室血压<130/80 mm Hg的患者为7.7%,8.4%接受治疗。采用平均日间血压,MH患病率为14%,按照ESH标准,接受治疗的患者中MUCH为15%,而按ACC/AHA指南则为28%~30%。使用平均24 h ABPM,对应血压值分别为20%和39%。与正常诊室和动态血压患者相比,MH或MUCH与心血管风险较差相关,年龄越大、男性和吸烟者的诊室收缩压越高,且心血管疾病发病率增加。

该研究提示,在未经治疗和接受治疗的诊室血压正常的个体中,可观察到MH的高发病率,这为临床实践中ABPM的广泛运用提供了有力支持。

原始出处:
Alejandro de la Sierra, José R. Banegas, Ernest Vinyoles,et al. Prevalence of Masked Hypertension in Untreated and Treated Patients With Office Blood Pressure Below 130/80 mm Hg. Circulation. April 30, 2018.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1976567, encodeId=7d4919e6567ea, content=<a href='/topic/show?id=177f9156168' target=_blank style='color:#2F92EE;'>#诊室血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91561, encryptionId=177f9156168, topicName=诊室血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 15 22:29:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823460, encodeId=738f1823460a3, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Jun 26 06:29:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936097, encodeId=f40b193609ee9, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sun Apr 21 12:29:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315383, encodeId=59b331538362, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Tue May 15 18:28:01 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618453, encodeId=6b04161845311, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Tue May 15 02:29:00 CST 2018, time=2018-05-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1976567, encodeId=7d4919e6567ea, content=<a href='/topic/show?id=177f9156168' target=_blank style='color:#2F92EE;'>#诊室血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91561, encryptionId=177f9156168, topicName=诊室血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 15 22:29:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823460, encodeId=738f1823460a3, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Jun 26 06:29:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936097, encodeId=f40b193609ee9, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sun Apr 21 12:29:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315383, encodeId=59b331538362, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Tue May 15 18:28:01 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618453, encodeId=6b04161845311, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Tue May 15 02:29:00 CST 2018, time=2018-05-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1976567, encodeId=7d4919e6567ea, content=<a href='/topic/show?id=177f9156168' target=_blank style='color:#2F92EE;'>#诊室血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91561, encryptionId=177f9156168, topicName=诊室血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 15 22:29:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823460, encodeId=738f1823460a3, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Jun 26 06:29:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936097, encodeId=f40b193609ee9, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sun Apr 21 12:29:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315383, encodeId=59b331538362, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Tue May 15 18:28:01 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618453, encodeId=6b04161845311, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Tue May 15 02:29:00 CST 2018, time=2018-05-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1976567, encodeId=7d4919e6567ea, content=<a href='/topic/show?id=177f9156168' target=_blank style='color:#2F92EE;'>#诊室血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91561, encryptionId=177f9156168, topicName=诊室血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 15 22:29:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823460, encodeId=738f1823460a3, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Jun 26 06:29:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936097, encodeId=f40b193609ee9, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sun Apr 21 12:29:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315383, encodeId=59b331538362, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Tue May 15 18:28:01 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618453, encodeId=6b04161845311, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Tue May 15 02:29:00 CST 2018, time=2018-05-15, status=1, ipAttribution=)]
    2018-05-15 1e127dd4m40(暂无匿称)

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1976567, encodeId=7d4919e6567ea, content=<a href='/topic/show?id=177f9156168' target=_blank style='color:#2F92EE;'>#诊室血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91561, encryptionId=177f9156168, topicName=诊室血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 15 22:29:00 CST 2019, time=2019-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823460, encodeId=738f1823460a3, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Jun 26 06:29:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936097, encodeId=f40b193609ee9, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sun Apr 21 12:29:00 CST 2019, time=2019-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315383, encodeId=59b331538362, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4cyIbibqa2VuNGCKeyRxITYNqLTIaoFo3Jx2LSawp8yrFSs1CIXKv1jyXV97ecnxhhktGKkPP9onfJFZCbiayLgic/0, createdBy=3f1c1956638, createdName=1e127dd4m40(暂无匿称), createdTime=Tue May 15 18:28:01 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618453, encodeId=6b04161845311, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Tue May 15 02:29:00 CST 2018, time=2018-05-15, status=1, ipAttribution=)]

相关资讯

ASH 2014:夜间血压——预测患者的临床预后指标

"尽管24小时动态血压监测(ABPM)测量日间和夜间血压已开展多年,但目前仍不清楚哪些指标能预测患者的临床预后。"——George Roush博士美国时间5月16日至20日,第29界美国高血压学会(ASH)科学年会于纽约市举行。会议期间公布的一项大型荟萃分析显示,诊室血压与心血管疾病预后(包括卒中)之间无相关性,相反,夜间血压与不良临床预后风险相关,夜间收缩压每升高10 mmHg,心血管不良预后风

JAMA Intern Med:装置引导呼吸未能显著降低诊室血压

荷兰一项荟萃分析表明,与音乐治疗和假装置相比,装置引导呼吸(DGB)未能显著降低诊室血压。相关论文9月15日在线发表于《美国医学会杂志·内科学》(JAMA Intern Med)。 研究者检索了Medline、EMBASE、clinicaltrials.gov和Cochrane数据库,并纳入了持续时间最少4周、采用双盲或单盲设计、具有活性对照组的DGB试验。主要转归指标为诊室血压。 结果显示,

NEJM:动态血压较诊室血压更能预测死亡

与诊室或家庭单次偶测血压相比,动态血压监测能获得更全面的血压信息,并具有识别特殊类型高血压(如白大衣高血压、隐匿性高血压和夜间高血压)的优势从而减少漏诊误诊。